Insulin degludec
- Generic Name
- Insulin degludec
- Brand Names
- Ryzodeg, Tresiba, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 844439-96-9
- Unique Ingredient Identifier
- 54Q18076QB
- Background
Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. ...
- Indication
Insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1108
- Registration Number
- NCT02500706
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Taoyuan, Taiwan
Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1262
- Registration Number
- NCT02392117
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom
Effects of Shifting From Twice Daily Insulin Glargine or Detemir to Once Daily Insulin Degludec in Type 1 Diabetes
- First Posted Date
- 2015-02-10
- Last Posted Date
- 2016-08-16
- Lead Sponsor
- University of Padova
- Target Recruit Count
- 26
- Registration Number
- NCT02360254
- Locations
- 🇮🇹
Division of Metabolic Diseases, University Hospital of Padova, Padova, Italy
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2014-05-28
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 49
- Registration Number
- NCT02148861
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India
- Conditions
- Interventions
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1056
- Registration Number
- NCT02117622
- Locations
- 🇮🇳
Novo Nordisk Investigational Site, Thriruvananthapuram, India
A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2019-01-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 501
- Registration Number
- NCT02034513
- Locations
- 🇵🇷
Novo Nordisk Investigational Site, Manati, Puerto Rico
A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2014-01-08
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 721
- Registration Number
- NCT02030600
- Locations
- 🇵🇷
Novo Nordisk Investigational Site, San Juan, Puerto Rico
Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®
- Conditions
- Interventions
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2020-08-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 6163
- Registration Number
- NCT01984372
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events
- Conditions
- Interventions
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 7637
- Registration Number
- NCT01959529
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wolverhampton, United Kingdom
A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes
- First Posted Date
- 2013-06-19
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 458
- Registration Number
- NCT01880736
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Yokkaichi-shi, Mie, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.